The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
MEK in cancer and cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
De Luca, A., Maiello, M. R., D'Alessio, A., Pergameno, M., & Normanno, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.639361 · Cited by 735
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2899 · Cited by 567
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK
Allan, L. A., Morrice, N., Brady, S., Magee, G., Pathak, S., & Clarke, P. R. (2003) · Nature Cell Biology · doi:10.1038/ncb1005 · Cited by 474
The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
Ramos, J. W. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.04.009 · Cited by 474
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
Impact of EGFR expression on colorectal cancer patient prognosis and survival
Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi006 · Cited by 462
Integrating the MAP kinase signal into the G1 phase cell cycle machinery
Roovers, K., & Assoian, R. K. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<818::aid-bies7>3.0.co;2-6 · Cited by 458
Ras oncogenes and their downstream targets
Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Ballif, B. A., & Blenis, J. (2001) · PubMed · Cited by 427
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., et al. (2012) · Nature Genetics · doi:10.1038/ng.1026 · Cited by 409
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382
Resistance to BRAF-targeted therapy in melanoma
Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 374
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma
Onken, M. D., Worley, L. A., Long, M. D., Duan, S., Council, M. L., Bowcock, A. M., & Harbour, J. W. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2145 · Cited by 346
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303
伊藤, 善. (1998) · doi:10.11501/3155565 · Cited by 300
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 278
Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., Le Roux, C., & Raoul, J. (2012) · Cancer · doi:10.1002/cncr.26255 · Cited by 275
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Janku, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 249
Ueda, S., Ogata, S., Tsuda, H., Kawarabayashi, N., Kimura, M., Sugiura, Y., Tamai, S., Matsubara, O., Hatsuse, K., & Mochizuki, H. (2004) · Pancreas · doi:10.1097/00006676-200407000-00061 · Cited by 245
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 244
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
Safaee Ardekani, G., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047054 · Cited by 224
Potential Tumor Suppressive Pathway Involving DUSP6/MKP-3 in Pancreatic Cancer
Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., & Horii, A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64315-5 · Cited by 216
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 216
Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma
Schmidt, C. M., McKillop, I. H., Cahill, P. A., & Sitzmann, J. V. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6840 · Cited by 212
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 211
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210
Yeh, J. J., Routh, E. D., Rubinas, T., Peacock, J., Martin, T. D., Shen, X. J., Sandler, R. S., Kim, H. J., Keku, T. O., & Der, C. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0972 · Cited by 172
Halilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3a3 · Cited by 162
The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery
Neel, N. F., Martin, T. D., Stratford, J. K., Zand, T. P., Reiner, D. J., & Der, C. J. (2011) · Genes & Cancer · doi:10.1177/1947601911407329 · Cited by 153
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-26 · Cited by 152
O’Neil, B. H., Goff, L. W., Kauh, J. S. W., Strosberg, J., Bekaii‐Saab, T., Lee, R.-M., Kazi, A., Moore, D. T., Learoyd, M., Lush, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9432 · Cited by 151
Gysin, S., Lee, S., Dean, N. M., & McMahon, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2848 · Cited by 149
Hayashi, J., Aoki, H., Kajino, K., Moriyama, M., Arakawa, Y., & Hino, O. (2000) · Hepatology · doi:10.1053/jhep.2000.19343 · Cited by 147
Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T. A., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 141
Balmanno, K., Chell, S. D., Gillings, A. S., Hayat, S., & Cook, S. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24604 · Cited by 140
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Jing, J., Greshock, J. D., Holbrook, J. D., Gilmartin, A. G., Zhang, X., McNeil, E., Conway, T. M., Moy, C. H., Laquerre, S. G., Bachman, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0505 · Cited by 135
Corcoran, R. B., Settleman, J. E., & Engelman, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.262 · Cited by 133
Giambartolomei, S., Covone, F., Levrero, M., & Balsano, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204372 · Cited by 133
Coles, L. C., & Shaw, P. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205302 · Cited by 126
Cooperative Regulation of the Cell Division Cycle by the Protein Kinases RAF and AKT
Mirza, A. M., Gysin, S., Malek, N. P., Nakayama, K. I., Roberts, J. M., & McMahon, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10868-10881.2004 · Cited by 123
Ambrosini, G., Pratilas, C. A., Qin, L., Tadi, M., Surriga, O., Carvajal, R. D., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3086 · Cited by 115
Targeting MAPK pathway in melanoma therapy
Cheng, Y., Zhang, G., & Li, G. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9433-9 · Cited by 113
Holt, S. V., Logié, A., Odedra, R., Heier, A., Heaton, S. P., Alférez, D., Davies, B. R., Wilkinson, R. W., & Smith, P. D. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.8 · Cited by 112
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Neuzillet, C., Hammel, P. R., Tijeras‐Raballand, A., Couvelard, A., & Raymond, É. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9396-2 · Cited by 99
Self-citationHolt, S. V., Logié, A., Davies, B. R., Alférez, D., Runswick, S. K., Fenton, S. E., Chresta, C. M., Gu, Y., Zhang, J., Wu, Y.-L. L. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1780 · Cited by 91
Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L. D., Ko, M., Aguirre, S. A., & Younis, H. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0060 · Cited by 90
Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
Faivre, S. J., Zappa, M., Vilgrain, V., Boucher, É., Douillard, J., Lim, H. Y., Kim, J. S., Im, S., Kang, Y., Bouattour, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1708 · Cited by 90
Self-citationYun, C., Cho, H., Kim, S.-J., Lee, J., Park, S. Y., Chan, G. K. T., & Cho, H. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.159.2.3 · Cited by 89
Williams, T. M., Flecha, A. R., Keller, P., Ram, A. N., Karnak, D. M., Galbán, S., Galbán, C. J., Ross, B. D., Lawrence, T. S., Rehemtulla, A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0098 · Cited by 81
Wang, H., Daouti, S., Li, W., Yang, W., Rizzo, C., Higgins, B., Packman, K. E., Rosen, N. X., Boylan, J. F., Heimbrook, D. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4351 · Cited by 76
Chen, L., Shi, Y., Jiang, C., Wei, L., Wang, Y.-L., & Dai, G. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.01.023 · Cited by 74
Tan, X., Egami, H., Abé, M., Nozawa, F., Hirota, M., & Ogawa, M. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.025338 · Cited by 74
Epithelial-to-Mesenchymal Transition in Pancreatic Adenocarcinoma
Cano, C. E., Motoo, Y., & Iovanna, J. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.183 · Cited by 70
BRAF and K-ras gene mutations in human pancreatic cancers
Ishimura, N., Yamasawa, K., Rumi, M. A. K., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00384-7 · Cited by 70
Fattore, L., Marra, E., Pisanu, M. E., Noto, A., Vitis, C. D., Belleudi, F., Aurisicchio, L., Mancini, R., Torrisi, M. R., Ascierto, P. A., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-180 · Cited by 67
Baudy, A. R., Dogan, T., Flores-Mercado, J. E., Hoeflich, K. P., Su, F., van Bruggen, N., & Williams, S. (2012) · EJNMMI Research · doi:10.1186/2191-219x-2-22 · Cited by 64
Garon, E. B., Finn, R. S., Hosmer, W., Dering, J., Ginther, C., Adhami, S., Kamranpour, N., Pitts, S. L., Desai, A. J., Elashoff, D. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0037 · Cited by 63
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63
Martin, V., Botta, F., Zanellato, E., Molinari, F., Crippa, S., Mazzucchelli, L., & Frattini, M. (2012) · PubMed · doi:10.14670/hh-27.785 · Cited by 60
Molecular Biology of Pancreatic Ductal Adenocarcinoma Progression
Rhim, A. D., & Stanger, B. Z. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385233-5.00002-7 · Cited by 51
Zhang, M., Ma, Q., Hu, H., Zhang, D., Li, J., Ma, G., Bhat, K., & Wu, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.017 · Cited by 48
Murphy, L. O., Cluck, M. W., Lovas, S., Ötvös, F., Murphy, R. F., Schally, A. V., Permert, J., Larsson, J., Knezetic, J. A., & Adrian, T. E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1698 · Cited by 46
Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition
Urick, M. E., Chung, E. J., Shield, W. P., Gerber, N. K., White, A. O., Sowers, A. L., Thetford, A., Camphausen, K. A., Mitchell, J. B., & Citrin, D. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0358 · Cited by 46
Specifically targeting ERK1 or ERK2 kills Melanoma cells
Qin, J., Xin, H., & Nickoloff, B. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-15 · Cited by 44
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.4170er2 · Cited by 44
MEK inhibitors: a patent review 2008 – 2010
Trujillo, J. I. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.577068 · Cited by 40
Jovanovic, B., Egyházi, S., Eskandarpour, M., Ghiorzo, P., Palmer, J. M., Bianchi‐Scarrà, G., Hayward, N. K., & Hansson, J. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.287 · Cited by 37
Chang, Q., Chapman, M. S., Miner, J. N., & Hedley, D. W. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-515 · Cited by 35
Development of Extracellular Signal-Regulated Kinase Inhibitors
Burkhard, K. A., Smith, S., Deshmukh, R. R., MacKerell, A. D., & Shapiro, P. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789044416 · Cited by 32
Tijeras‐Raballand, A., Neuzillet, C., Couvelard, A., Serova, M., Gramont, A. D. E., Hammel, P. R., Raymond, É., & Faivre, S. J. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0229-6 · Cited by 31
Self-citationChang, Q., Chen, E., & Hedley, D. W. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.20.9430 · Cited by 30
Tan, X., Tamori, Y., Egami, H., Ishikawa, S., Kurizaki, T., Takai, E., Hirota, M., & Ogawa, M. (2004) · Oncology Reports · doi:10.3892/or.11.5.993 · Cited by 26
The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines
Sahu, R. P., Batra, S., Kandala, P. K., Brown, T. L., & Srivastava, S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1463-1 · Cited by 26
Xu, J., Knox, J. J., Ibrahimov, E., Chen, E. X., Serra, S., Tsao, M., Cao, P. M., Vines, D. C., Green, D. E., Metran-Nascente, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2557 · Cited by 25
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
Little, A. S., Balmanno, K., Sale, M. J., Smith, P. D., & Cook, S. J. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110647 · Cited by 24
Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer
Ganti, A. K. (2010) · Cancer Investigation · doi:10.3109/07357900903476760 · Cited by 20
RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function
Schäfer, R., & Sers, C. (2011) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2010.11.005 · Cited by 12
Cited by
Compromised MAPK signaling in human diseases: an update
Kim, E. K., & Choi, E.-J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,020
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 612
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Current Development Status of MEK Inhibitors
Cheng, Y., & Tian, H. (2017) · Molecules · doi:10.3390/molecules22101551 · Cited by 291
Metadata
- Authors
- Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., & Raymond, E.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 141
- Issue
- 2
- Pages
- 160-171
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2065455574
- Cited by
- 264
- References
- 132
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.